Clinical Trial Update: An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects

View source ↗

Summary

An open-randomized, balanced crossover bioequivalence study is described comparing a 60 mg gliclazide modified-release tablet with two 30 mg gliclazide modified…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Hyperglycemia

Drugs mentioned

• Gliclazide Modified-Release 60 mg (gliclazide)

Snippet

Sponsor: Taipei Medical University WanFang Hospital | Conditions: Hyperglycemia, Diabetes | Status: UNKNOWN